Marketed in more than 60 countries,
tafluprost is a prostaglandin analogue Santen co-developed with Asahi Glass Co.,
Ltd.（Tokyo, Japan）for the treatment of glaucoma and elevated
intraocular pressure. In April 2009, Santen granted the U.S. licensing rights
for tafluprost to Merck.
Under the Agreement, Santen has certain
rights to receive royalties on sales of ZIOPTAN® from Oak Pharmaceuticals. The
Agreement is not expected to have a significant impact on Santen's consolidated
financial performance for the fiscal year ended March 31, 2014.
Founded in 1890, Santen is a global
company headquartered in Osaka, Japan. Santen researches, develops and markets
ophthalmic products for physicians worldwide. Among prescription ophthalmic
pharmaceuticals, Santen holds the top share within the Japanese market and is
one of the leading ophthalmic companies worldwide. Tokyo Stock Exchange code
4536. For more information, visit www.santen.com.
Akorn is a niche pharmaceutical company
engaged in the development, manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities located in Decatur,
Illinois, Somerset, New Jersey and Paonta Sahib, India where the Company
manufactures ophthalmic and injectable pharmaceuticals. Additional information
is available on the Company’s website at www.akorn.com. Akorn’s wholly-owned
subsidiary, Oak Pharmaceuticals, is engaged in the sales and marketing of
Information provided in this press
release contains so-called “forward-looking statements”. The realization of
these forecasts is subject to risk and uncertainty from various sources.
Therefore, please note that the actual results may differ significantly from the
forecasts. Business performance and financial conditions are subject to the
effects of changes in regulations made by governments in Japan and other nations
concerning medical insurance, drug pricing and other systems, as well as
fluctuations in market variables such as interest and foreign exchange
Director, Corporate Communication Europe
Tel: + 33 6 65 54 60 19